Meta-analysis of Trials Comparing Drug-eluting Stents with Bare Metal Stents: Safety and Efficacy

References (62)

1. 1 Measuring inconsistency in meta-analyses [DOI]
2. 2 Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes [DOI]
3. 3 Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes [DOI]
4. 4 Clinical End Points in Coronary Stent Trials [DOI]
5. 5 The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials [DOI]
6. 6 Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery [DOI]
7. 7 Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents [DOI]
8. 8 Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents [DOI]
9. 9 Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy [DOI]
10. 10 Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis [DOI]
11. 11 Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions [DOI]
12. 12 Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) [DOI]
13. 13 Pathology of Acute and Chronic Coronary Stenting in Humans [DOI]
14. 14 A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents [DOI]
15. 15 A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents [DOI]
16. 16 Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents [DOI]
17. 17 The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) [DOI]
18. 18 Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction [DOI]
19. 19 Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction [DOI]
20. 20 Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial [DOI]
21. 21 Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement [DOI]
22. 22 Bare metal stent restenosis is not a benign clinical entity [DOI]
23. 23 Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET) [DOI]
24. 24 Subacute Stent Thrombosis in the Era of Intravascular Ultrasound-Guided Coronary Stenting Without Anticoagulation: Frequency, Predictors and Clinical Outcome [DOI]
25. 25 Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI) [DOI]
26. 26 A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis [DOI]
27. 27 Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy [DOI]
28. 28 Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial [DOI]
29. 29 Prasugrel in Clinical Practice [DOI]
30. 30 Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial [DOI]
31. 31 Acute Coronary Syndrome May Occur With In-Stent Restenosis and Is Associated With Adverse Outcomes (The PRESTO Trial) [DOI]
32. 32 Single‐Center Randomized Evaluation of Paclitaxel‐Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION) [DOI]
33. 33 Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions [DOI]
34. 34 TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions [DOI]
35. 35 Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention [DOI]
36. 36 Comparison of Effectiveness and Safety of Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With Diabetes Mellitus (from the Italian Multicenter Randomized DESSERT Study) [DOI]
37. 37 A randomized comparison of sirolimus‐eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: The DECODE study [DOI]
38. 38 Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement [DOI]
39. 39 Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial) [DOI]
40. 40 One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial [DOI]
41. 41 Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study [DOI]
42. 42 Incremental Cost-Effectiveness of Drug-Eluting Stents Compared With a Third-Generation Bare-Metal Stent in a Real-World Setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET) [DOI]
43. 43 Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction [DOI]
44. 44 Changes in CCR2 Chemokine Receptor Expression and Plasma MCP-1 Concentration after the Implantation of Bare Metal Stents Versus Sirolimus-eluting Stents in Patients with Stable Angina [DOI]
45. 45 In‐stent Restenosis in Bare Metal Stents Versus Sirolimus‐eluting Stents After Primary Coronary Intervention for Acute Myocardial Infarction and Subsequent Transcoronary Transplantation of Autologous Stem Cells [DOI]
46. 46 Sirolimus-eluting vs. uncoated stents for prevention of restenosis in small coronary arteries: A randomized trial [DOI]
47. 47 Clinical Experiences Using Everolimus‐Eluting Stents in Patients with Coronary Artery Disease [DOI]
48. 48 A graphic framework for teaching critical appraisal of randomised controlled trials [DOI]
49. 49 Everolimus‐ and Zotarolimus‐Eluting Stents for Bare Metal Stent In‐Stent Restenosis Treatment: A Prospective Study [DOI]
50. 50 Phosphorylcholine-coated Dexamethasone Eluting Stent in the Prevention of Restenosis: A Randomized Trial in a Single Hospital
51. 51 Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study [DOI]
52. 52 Safety and Efficacy of Drug-Eluting and Bare-Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies [DOI]
53. 53 Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions [DOI]
54. 54 Analysis of 14 Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents [DOI]
55. 55 Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study [DOI]
56. 56 One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial [DOI]
57. 57 Actinomycin-eluting stent for coronary revascularization: A randomized feasibility and safety study: The ACTION trial [DOI]
58. 58 Paclitaxel-Eluting Stents Versus Bare-Metal Stents in Acute Myocardial Infarction
59. 59 Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the european evaluation of paclitaxel eluting stent (ELUTES) trial [DOI]
60. 60 Non–polymer-based, paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial [DOI]
61. 61 Drug-Eluting Versus Bare Metal Stents in Patients With ST-Segment–Elevation Myocardial Infarction. Eight-Month Follow-Up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) Trial [DOI]
62. 62 Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement*1 [DOI]

Cited by 0

No indexed citations yet.

Related research

• A Randomized Placebo Controlled Study to Determine the Efficacy of Oral Diclofenac Sodium in the Treatment of Symptomatic Osteoarthritis of the Knee in Nnewi, South Eastern Nigeria — shares topic coverage
• Bacteriological and Fungal Evaluation of Three Brands of Disinfectants Sold in Calabar Municipality, Cross River State — shares topic coverage
• Drug Interactions, Safety and Efficacy of Probiotics — shares topic coverage
• The Efficacy of the Volume of Hyperbaric Bupivacaine Used and Its Influence on Spinal Anaesthesia Induced Hypotension during Caesarean Section — shares topic coverage
• A Comparison of Efficacy of Two Brands of Enoxaparin in COVID-19 Patients: A Pilot Study — shares topic coverage